Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.

Almudena Cotes SanchísJavier Gallego PlazasRaquel HernandezVirginia ArrazubiAna CustodioJuana María CanoGema AguadoIsmael MaciasCarlos LopezFlora LópezLaura VisaMarcelo GarridoNieves Martínez LagoAna Fernández MontesMaría Luisa LimónAitor AzkáratePaola PimentelPablo RegueraAvinash RamchandaniJuan Diego CachoAlfonso Martín CarniceroMónica GranjaMarta Martín RichardCarolina Hernández PérezAlicia HurtadoOlbia SerraElvira BuxoMaría Del Rosario Vidal TocinoPaula Jimenez-FonsecaAlberto Carmona-Bayonas

Published in: PloS one (2020)

This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines.

Keyphrases

end stage renal disease
systematic review
ejection fraction
newly diagnosed
squamous cell carcinoma
radiation therapy
clinical trial
peritoneal dialysis
electronic health record
neoadjuvant chemotherapy
patient reported outcomes
big data
double blind
rectal cancer
locally advanced